Signal Bioscience unveiled a chemistry that separates nucleic acid amplification from signal generation to boost multiplexing in digital PCR and qPCR and is preparing a seed funding round to commercialize the approach. The Ann Arbor startup demonstrated up to 15-plex dPCR and plans to scale toward 50 targets per reaction, offering workflows compatible with standard lab instruments. CEO John Cunningham said the technology reduces fluorophore complexity and lowers per-assay costs, targeting infectious disease panels, antimicrobial resistance profiling and oncology mutation panels. The company is seeking commercial and clinical collaborators to validate applications and advance regulatory pathways.